| KO |
Report |
Net operating revenue |
BEAT |
pred ~$13.30B vs. cons $13.125B |
MEDIUM |
| KO |
Report |
Comparable diluted EPS |
IN-LINE |
pred ~$0.940 vs. cons $0.933 |
MEDIUM |
| KO |
Report |
Total volume growth |
BEAT |
pred ~+1.5% vs. cons +0.7% |
MEDIUM |
| KO |
Guide |
Comparable EPS growth (FY2026) |
UNCHANGED |
guide ~8%-9%, or $3.24-$3.27, vs. cons $3.268 |
MEDIUM |
| KO |
Guide |
Organic revenue growth (FY2026) |
UNCHANGED |
guide ~4%-5% vs. cons UNVERIFIED |
LOW |
| KO |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.5% |
— |
LOW |
| KO |
Return |
5-day cumulative residual |
+0.5% (STABILIZE) |
STABILIZE — initial sell-off partially recovers |
LOW |